Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a 5-year survival rate of only 6%. Although the cytosine analog gemcitabine is the drug commonly used to treat PDAC, chemoresistance unfortunately renders the drug ineffective. Thus, strategies that can decrease this resistance will be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Xu, Dapeng, Cobb, Michael G., Gavilano, Lily, Witherspoon, Sam M., Williams, Daniel, White, Catherine D., Taverna, Pietro, Bednarski, Brian K., Kim, Hong Jin, Baldwin, Albert S., Baines, Antonio T.
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2013
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3813565/
https://ncbi.nlm.nih.gov/pubmed/23760491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24343
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados